Vanessa Brill, Vice President and Regional General Counsel for Dr. Reddy’s Laboratories operations in the Americas, discusses various topics including what she looks for in outside legal counsels and drug supply chain issues.
Sanofi is rumored to have a $50 billion budget for mergers and acquisitions and is taking a look at U.S.-based biotech companies, including South San Francisco-based Principia Biopharma.
In a review of recently published scientific studies, researchers with Queen Mary University of London discovered a gene that naturally suppresses the signs of Alzheimer’s disease in human brain cells.
A dramatic increase in Covid-19 testing and tracing is needed in order to put the United States on a surer path through the pandemic. But that diagnostics increase comes with a significant price tag of about $75 billion from the federal government, the Rockefeller Foundation said in its latest report.
Frost & Sullivan IDs Five New Technologies to Power Research Across Preclinical Disease Models Published: July 16, 2020 BioSpace When the CEOs of young, innovative biotech companies discuss how their […]
Phase I data from the Covid-19 vaccine under development by AstraZeneca and Oxford University’s Jenner Institute is showing a robust defense against the novel coronavirus that has infected more than 13 million people across the globe.
Johnson & Johnson is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of a potential COVID-19 vaccine in advance of the company producing any of the medicines, the company’s Chief Financial Officer Joseph Wolk told Reuters in an interview.
AC Immune initiated the second highest dosing group in the company’s Phase Ib/IIa clinical trial of ACI-35.030 for Alzheimer’s disease, based on encouraging interim data from the initial dosing cohort.
Novartis’ Sandoz division will not profit from 15 generic drugs the company is making available to developing countries to treat symptoms of Covid-19 for the pandemic’s duration, the Swiss drugmaker said.
Merck CEO Ken Frazier says the first vaccines against Covid-19, should they meet the 50 percent efficacy threshold set by the U.S. Food and Drug Administration, may not have as broad of an impact as hoped.
